University of Southampton, Clinical Neurosciences Division, Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, Hampshire, United Kingdom
Jay Amin completed his medical training in Hampshire before specialising in Old Age Psychiatry. He also works for a dementia clinical trials unit in Southampton. He is now a Clinical Research Fellow funded by Alzheimer’s Research UK and involved in a research study investigating the role of the immune system in Dementia with Lewy bodies and Alzheimer’s Disease.
The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom
Michael Berridge is an Emeritus Babraham Fellow at the Babraham Institute in Cambridge. His main research interest concerns the role of calcium (Ca2+) in cellular control processes. Recently, his attention has focused on the role of Ca2+ and Vitamin D in Alzheimer’s disease.
For his work on second messengers Berridge has received numerous prizes, including The Louis Jeantet Prize in Medicine, The Albert Lasker Medical Research Award, The Heineken Prize, The Wolf Foundation Prize in Medicine and The Shaw Prize. In 1998 he was knighted for his service to science.
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, United States
Anna Borisovskaya, MD, is originally from Ukraine. She graduated from University of Washington School of Medicine in 2005 and completed her residency in Psychiatry and fellowship in Geriatric Psychiatry in the same situation in 2009 and 2010, respectively. Currently, she works as a psychiatrist at the Veterans’ Affairs Medical Center in Seattle, WA, USA, where she is also the Director of ECT. Her academic interests and publications have focused on improving the practice of electroconvulsive therapy and improving care in dementia. She is also interested in consultation-liaison Psychiatry and in psychodynamic therapy, having completed the training with Seattle Psychoanalytic Society and Institute.
Institute of Biomedical Research of Barcelona, Spain
Dr. Anna Colell is a full tenured scientist in the department of Cell Death and Proliferation at the Institute of Biomedical Research of Barcelona since 2009. Previously, she trained in mitochondria and cell death signalling at La Jolla Institute for Allergy and Immunology, San Diego (CA). Her main research interests are focused in understanding how changes in brain cholesterol and mitochondrial oxidative stress can contribute to neurodegeneration.
University of South Florida, Tampa, United States
Dr. Ming Chen got his Ph.D. from the State University of New York and Postdoc training at Harvard University. During the course of studies, he has pinpointed the unique roles of Ca2+ signaling and Ca2+-dependent enzymes in the formation of plaques and tangles during aging and deduced the key roles of “risk factors” in the origins of sporadic Alzheimer’s disease (sAD). Based on a comprehensive analysis of the disease features, he propose that sAD must be understood as a senile disorder, not a “discrete disease”, and that “energy and Ca2+ signaling deficits” are the rational drug targets for intervention.
Case Western Reserve School of Medicine, Cleveland, OH, United States
Dr. Costa is Professor of Pediatrics and Psychiatry, Director of the Intellectual Disabilities Program at the Research Institute for Children’s Health, Case Western Reserve University. He has spent 20 years investigating the neurobiology of Down syndrome, searching for potential pharmacotherapies to enhance cognition and/or prevent the development of Alzheimer-type dementia in persons with this genetic disorder. He translated preclinical findings by his group into a pilot study that showed a small, but significant effect of memantine treatment on one measure of long-term memory in persons with Down syndrome. A follow-up study of memantine in Down syndrome is currently underway.
The University of Melbourne, Melbourne, Australia
Asociate Professor Peter Crack heads the Neuropharmacology laboratory in the Department of Pharmacology and Therapeutics at the University of Melbourne. His research interests include the contribution that neuroinflammation plays in the progressoin of both ac #ageing #healthyageingute neural injury and chronic neural pathologies.
University of New South Wales, Sydney, NSW, Australia
Anthony Don runs a lipid biochemistry and metabolomics research team at UNSW Australia. For his PhD, completed in 2004, Dr Don was instrumental in the development of a new class of anti-cancer agents that target mitochondrial metabolism in tumours and are now in clinical trials. He undertook postdoctoral research at the Scripps Research Institute, USA, before returning to UNSW Australia to establish a research group. Dr Don employs new mass spectrometry and biochemical assays for lipid metabolism, in combination with brain bank tissue, to improve our understanding of biochemical changes that pre-dispose to the development of Alzheimer’s Disease.
Indiana University School of Medicine, Indianapolis, United States
Dr. Du has a broad background in drug development and animal models in Alzheimer disease and other neurodegenerative disorders, with specific training and expertise in immunization research areas for this application. As a scientist at Lilly, I carried out molecular, cellular and animal research and genotyping data analysis on neurologicall aspects of drug development. He laid the groundwork for the proposed research by developing mechanistic and therapeutic studies for Alzheimer’s disease, Prion disease, Hypoxia-induced neuronal injury, Parkinson disease, Amyotrophic Lateral Sclerosis and other neurodegenerative disorders. In addition, Dr. Du successfully administered the projects, collaborated with international/national researchers, and produced many peer-reviewed publications from each project. As an established investigator, he has a demonstrated record of successful and productive research projects in an area of high relevance for Alzheimer disease research.
ARC Future Fellow, School of Biological Sciences, Illawarra Health and Medical Research Institute, University of Wollongong, Australia
Associate Professor Heath Ecroyd is a co-founding member and group leader in the ‘Proteostasis and Disease Research Group’ within the Illawarra Health and Medical Research Institute. His main research focus is the role chaperone proteins plays in preventing the aggregation of proteins associated with neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and Motor Neurone Disease. He has active research programs in (i) the structure-function relationship of the small heat shock chaperone proteins; (ii) the heat shock response pathway and its role in protein homeostasis (proteostasis); and (iii) extracellular proteostasis.
Sandra E. Encalada, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, CA, United States
Sandra Encalada is the Arlene and Arnold Assistant Professor in the Departments of Molecular and Experimental Medicine, and Moelcular and Cellular Neuroscience at The Scripps Research Institute. Her laboratory is interested in characterizing the interactions between molecular motors and their vesicular cargo that regulate intracellular transport in neurons. Sandra’s laboratory also integrates and extends the knowledge of motor regulation to dissect the role that defective vesicular transport plays in the accumulation of misfolded proteins inside axons to cause neurodegeneration. Using Caernorhabditis elegas and mice, the Encalada lab generates models of neurodegenerative disease including the transthyretin amyloidoses, Alzheimer’s and Prion diseases.
Born in 1965 in Greece, I obtained my MD degree in the University of Athens in 1989 before completing a full training on psychiatry and psychotherapy in London (Maudsley Hospital and Geneva) as well as postdoc training in Paris (La Pitié-Sâlpetrière Hospital, Federation of Neurology). In 1998, aged 33 years, I have been appointed as associate professor and medical head of the Division of Geriatric Psychiatry of the University Hospitals of Geneva. Later on (2004) I obtained the position of full tenured professor of Psychiatry in the University of Geneva. From 2003 to 2011, I also assumed a parallel position of full professor of Old Age Psychiatry in the University of Lausanne. I have been Chairman of the Department of Psychiatry in Geneva for 10 years. To date, I’m the Medical Director of Forensic Psychiatry and Medical Head of the Division of General psychiatry in The University Hospitals of Geneva.My research field was initially that of the functional neuroanatomy of dementing conditions and may be illustrated by a series of clinico-pathological studies aiming to determine the relative weight of each aging-related lesion in cognitive deterioration.
Karl Herholz, University of Manchester, Manchester, United Kingdom
Karl Herholz is Professor in Clinical Neuroscience at the University of Manchester. He leads neuroscience research at the Wolfson Molecular Imaging Centre with particular research interest in the use of positron emission tomography (PET) for early diagnosis and prevention of dementia, imaging of specific transmitter systems and deposition of pathological proteins. He is also Honorary Consultant at Salford Royal Hospital and the Nuclear Medicine Department, Central Manchester Foundation Trust. Before joining Manchester University he worked as a clinical neurologist and professor of neurology at University Hospital and the Max-Planck Institute for Neurological Research in Cologne, Germany.
He has leading roles in several international multicentre PET studies, including Early Diagnosis of Neurodegenerative Diseases within the EU-funded Networks on Diagnostic Molecular Imaging (DiMI), Imaging of Neuroinflammation in Neurodegenerative Diseases (INMiND) and the European Medical Information Framework on Alzheimer’s Disease (EMIF-AD, IMI/FP7). He is also leading the clinical PET imaging workgroup of the Dementia Platform UK and is a member of the Medical Research Council Neuroscience and Mental Health Board. His research has been published in more than 400 research papers (ISI H-index 67) and several books.
Charlotte Jendresen, Department of Pharmacology, University of Oslo and Oslo University Hospital, Oslo, Norway
Charlotte holds a M.Sc. in Human Biology from University of Copenhagen, Denmark. Her interest is in neurodegenerative diseases starting with research on CNS demyelination in cerebral malaria. She moved to Norway in 2012, and is currently in the final stage of her PhD at University of Oslo. Her research focuses on the involvement of heparan sulfate proteoglycans in Alzheimer disease (AD) – particularly with regard to the aggregation, deposition, and spreading of amyloid-beta in the brain. She also studies neuroinflammation in AD focusing on microglial involvement, TREM2, and heparan sulfate proteoglycans.
Dr. Andis Klegeris began studying cellular and molecular mechanisms of neurodegenerative diseases during his thesis work at the University Department of Pharmacology, Oxford University, UK. His interest in neuroinflammatory processes led him to the University of British Columbia in Vancouver, Canada, where Dr. Klegeris did his post-doctoral studies. Currently he is an Associate Professor of Pharmacology at the Department of Biology, University of British Columbia Okanagan Campus in Canada. Identification of novel treatment options for neurodegenerative diseases and mechanisms of intercellular signaling between neurons and glial cells are the main research focuses of his laboratory.
Dr. Köhler studied medicine at the Universities of Ulm and Heidelberg/Mannheim, Germany. He completed his doctorate in Anatomy at the University of Heidelberg in 1991 and worked in surgery, general medicine, and psychiatry. Dr. Köhler joined the Department of Neuroanatomy at the University Hospital in Cologne, Germany, in 1999. He is head of a laboratory for histochemistry and teaches medical students in gross anatomy and neuroanatomy. His major research interest is mechanisms of neurodegeneration that are caused by pathological alterations of protein tau.
Graduated from Istanbul Medicine Faculty- 1988. After residency in Ophthalmology completed Neuro-ophthalmology Clinical Fellowship at Michigan State University in 1995. After private practice, became an Asst. Prof. at Uskudar University in 2015.
John BJ Kwok, Neuroscience Research Australia, Sydney, Australia
Associate Professor John Kwok was awarded his PhD at the University of Cambridge in 1994. In 2003, he was awarded an R Douglas Wright Biomedical Career Development Award (NHMRC) in 2003 to work on the genetics of Alzheimer’s disease. Since 2006, he was recruited to head his own laboratory at Neuroscience Research Australia where he has pursued his interest in the roles of genetics and epigenetics in neurodegenerative diseases. In the past 5 years, Associate Professor Kwok has published 40 peer-reviewed articles, including a commissioned review on the genetics of dementia in the LANCET journal.
Slavica Krantic, UPMC, CNRS, Paris, France
Dr Krantic received her PhD in 1986 (University Paris XI) and was a Post-Doctoral Fellow in the Neuroscience department with Dr. Rémi Quirion (DMHUI, Montréal, Canada) until 1989. In 1990 she got a permanent Researcher position at the Centre National de la Recherche Scientifique (France). In 2008, Canadian Institutes of Health Research has appointed Dr. Krantic as a visiting scientist at McGill University. After her return to France in 2011, she joined the Centre de Recherche des Cordeliers (Paris) where she is the Principal Investigator of the research program aimed on identification of the earliest diagnostic markers for Alzheimer’s disease.
Ms. Rishika Kundra is a Dr. Manmohan Singh Scholar at St. John’s College, University of Cambridge, UK, pursuing her PhD in the department of Chemistry with Prof. Christopher M Dobson. Her work is focussed on understanding the behaviour of inherently metastable, aggregation prone proteins in neurodegenerative disorders like Alzheimer’s and Parkinson’s. She’s also interested in the regulation of these proteins in healthy states and how it is compromised in the face of defective protein homeostasis in ageing and disease.
Val Lowe, Mayo Clinic Rochester, Rochester, United States
Val J. Lowe, MD is a Professor of Radiology at Mayo Clinic, Rochester, Minnesota, and is the director of the Mayo Clinic Molecular Imaging Resource. He trained in nuclear medicine at Duke University. Dr. Lowe has served on numerous NIH review committees and panels. He has over 300 peer-reviewed publications, several patents and has funding through 22 NIH grants to study imaging.
Dr. Lowe and collaborators at Mayo Clinic are evaluating the utility of metabolic (FDG PET), amyloid (PiB PET) and tau PET multimodality brain imaging as part of a larger research project at Mayo Clinic on the development of neurodegenerative disease in the aging population.
Oleksandr Makarenko, Pereyaslav-Khmelnitskiy Pedagogical University named after H.Skovoroda, Kyiv, Ukraine
Makarenko O.M. has taken PhD degree at the age of 30 at the Moscow Medical Stomatological Institute, M.D. degree at the age of 40 at the Institute of higher nervous activity in Moscow. He carries out his post-dock researches at the Institute of Higher Nervous Activity and T. G. Shevchenko National University of Kyiv. He is a Professor of the Psychology Department, the author of more than 100 articles in reputed journals and 5 monographs (Lambert Academic Publishing).
Vasiliki Orgeta, University College London, London, United Kingdom
Dr Vasiliki Orgeta is a Senior Research Associate at the Division of Psychiatry, University College London and a Senior Research Fellow of the Alzheimer’s Society. She joined UCL in 2008, and since then has been involved in systematic reviews of psychological treatments for people with dementia, and has led several psychosocial trials in the field. She currently leads the development of a psychological intervention to prevent depressive symptoms in people with early-stage dementia, work funded by the Alzheimer’s Society. She also leads a new MSc in Dementia and Mental Health, at University College London.
Bettina Platt, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, Scotland, United Kingdom
Professor Bettina Platt, FSB, holds the Chair in Translational Neuroscience at the University of Aberdeen and has worked in the field of neurodegenerative diseases for over 18 years. She is heading a multi-disciplinary research team investigating brain function from the molecular to the functional level, with a particular emphasis on translational techniques. She currently leads the Scottish Alzheimer Research UK (ARUK) network and co-leads the Alzheimer’s Society-funded Scottish Doctoral Training Centre. She is also a member of the ARUK Grant Review Board, the Alzheimer’s Society Grant Advisory Board and the Scottish Dementia Research Consortium.
Yuriy Pankratov, University of Warwick, School of Life Sciences, Coventry, United Kingdom
Dr Yuriy Pankratov is an Associate Professor of Neuroscience in the University of Warwick. His group carries our a fundamental research into cellular neuroscience, in particular synaptic transmission and glia-neuron signalling. In recent years, his research took a special focus on the impact of ageing on the brain function.
Jane Rylett, Schulich Medicine & Dentistry, London, Ontario, Canada
Dr. Jane Rylett is a cellular and molecular neurobiologist recognized internationally for contributions in the areas of cholinergic neuron function, aging brain and Alzheimer’s disease. Her group carries out mechanistic studies on neurochemical changes in aging brain, responses of neurons to changes in the brain microenvironment and susceptibility to dementia. She is Professor and Chair of the Department of Physiology and Pharmacology at the University of Western Ontario in London, Ontario, Canada and a Scientist in the Molecular Medicine Group at Robarts Research Institute. She is also leader of the Primary Prevention Theme of the Canadian Consortium on Neurodegeneration in Aging.
Angela Scibetta, Ronchis, Italy
She was born on 11th March 1967. She lives in Italy, district Udine. She got a degree in medicine, in the University of Catania, passed with 110/110.
She starts working on June 1995 as tourist doctor and general medicine. On 2011 she got a degree in psychotherapy, passed with 30/30, ISP of Rome.
Hobby: Neuropsychology, Hypnosis, Dementia.
Cynthia M. Stonnington, Mayo Clinic College of Medicine, Scottsdale, United States
Dr. Cynthia Stonnington is Chair of Psychiatry & Psychology at Mayo Clinic in Arizona. She completed medical school at Mayo Medical School in Rochester, Minnesota, her residency training in Psychiatry at Stanford University Medical Center, and a Clinical Research Fellowship in brain imaging at University College London’s Wellcome Trust Centre for Neuroimaging. An Associate Professor of Psychiatry, her research interests include: 1) Applying neuroimaging methods to predict cognitive decline; 2) Exploring the neuropsychiatric underpinnings of psychosomatic illness; and 3) Identifying and testing interventions that can increase resilience in the face of illness or risk for illness.
Adrien W. Schmid, Ecole Polytechnique Fédérale de Lausanne (EPFL), Proteomics Core Facility, Life Sciences, Lausanne, Switzerland
Dr. Adrien Schmid is a trained neurophysiologist from the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL), were he leads several projects in the field of neurodengenerative diseases. He has developed expertise in the field targeted and quantitative mass spectrometry which he applies for new biomaker discovery studies in the research field of Alzheimer’s and Parkinson’s disease.
Louise Serpell, University of Sussex, Falmer, United Kingdom
Professor Louise Serpell has been working on understanding the molecular mechanisms that lead to Alzheimer’s disease for over 20 years. She c–chair of the Dementia Research group at the University of Sussex and leads a research group who work to discover how Abeta and tau are involved in Alzheimer’s.
Magdalena Sastre, Division of Brain Sciences, Hammersmith Hospital, Imperial College London, London, UK
Dr. Magdalena Sastre graduated in Sciences and did her PhD in Biology and Health Sciences at the University of the Balearic Islands, Spain. She trained in Neuroscience in the USA (Cornell University and New York University) and in Germany (Universities of Munich, Bonn and Frankfurt).
She is interested in the molecular mechanism by which inflammation affects neurodegenerative diseases, in particular Alzheimer’s disease.
Her scientific contributions include the study of the intracellular signalling cascade of the amyloid precursor protein and how it affects its cleavage and the formation of amyloid-β peptide. In addition, she has focused her research in the use of anti-inflammatory drugs as potential therapy for neurodegenerative diseases, and in the cofactors of the peroxisome proliferator-activated receptor-γ (PPAR-γ).
Michal Schwartz, The Weizmann Institute of Science, Rehovot, Israel
Schwartz is a Professor of Neuroimmunology, holding The Maurice and Ilse Katz Professorial chair in Neuroimmunology, at the Weizmann Insititue of Science Israel. She focuses on the role of innate and adaptive immunity in central nervous system plasticity in health and disease. She is the world pioneer in demonstrating that circulating immune cells are needed for CNS maintenance and repair. Her publications (H factor 90; Google Scholar), include numerous peer-reviewed articles and invited reviews, many of which appear in the most highly ranked journals. Schwartz has received a number of prestigious awards and is the elected incoming president of the International Societies for Neuroimmunology (2016).
Hari Shanker Sharma, Director of Research (International Experimental Central Nervous System Injury & Repair, IECNSIR), University Hospital, Uppsala University is Professor of Neurobiology (MRC), Docent in Neuroanatomy (UU) and is currently affiliated with Department of Surgical Sciences, Division of Anesthesiology and Intensive Care Medicine, Uppsala University, Sweden. Dr. Sharma on his research on brain pathology and neuroprotection in different models received the prestigious awards from The Laerdal Foundation of Acute Medicine, Stavanger, Norway, in 2005 followed by Distinguished International Scientists Collaboration Award by National Institute on Drug Abuse (NIDA), Baltimore, MD (2006–2008). His recent work on 5-HT3 receptor mediated neuroprotection in morphine withdrawal induced neurotoxicity won the coveted prize of Best Investigator Award 2008 and Best Scientific Presentation by European Federation of the International Association for Study of Pain (ISAP).
Joan Smith Sonneborn, a Professor Emeritus from the Zoology and Physiology Department at the University of Wyoming, focuses on how threshold levels of stress, including exercise stress, can trigger beneficial rejuvenation and anti aging effects on the brain and body and disease intervention. Her 2015 presentations include current research findings in Pro-survival neuron therapy for Alzheimer’s Disease, and Novel Drugs for HIV intervention. Intervention in aging and related diseases have been her passion especially using animal model systems’ strategies to tap into our natural reserves to tolerate challenges and preserve or activate energy systems. Her education includes her BA from Bryn Mawr College, and PhD from Indiana University, with postdoctoral training at Brandeis University and University of California, Berkeley.
Mercedes Unzeta is Professor Emeritus of the Biochemistry Department (Faculty of Medicine), Universitat Autonoma de Barcelona (UAB). Visiting professor at the Biochemistry Department of Trinity College, Dublin (Ireland). Charter member and Researcher of the Neuroscience Institute (UAB) and more than 100 indexed publications in the main international journals. Dr M.Unzeta research interests are focused on neurodegenarative disease specially regarding Alzheimer´s disease and its therapeutic approach by the design and biological assessment of new MTDL molecules. Moreover she is interested in the contribution of the SSAO/VAP-1 Oxidase to the neurovascular disfunction and its relationship with the Stroke and Alzheimer´s disease.
Annalena Venneri, Department of Neuroscience, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK
Professor Venneri joined the University of Sheffield in 2011 as Professor of Clinical Neuropsychology and is leading the dementia research programme focused on early and differential diagnosis of Alzheimer’s disease. Her research interests include: identifying cognitive and imaging biomarkers of neurodegeneration; optimizing neuroimaging methods for the evaluation of pharmacological and non pharmacological treatment in Alzheimer’s disease and other neurodegenerative disorders; studying the influence of modifiable lifestyle risk factors to prevent cognitive decline. She is also a Honorary Consultant for Sheffield Teaching Hospitals NHS Trust and the Scientific Director of the IRCCS San Camillo Hospital, Venice, Italy. She is a member of the editorial board of several neuroscience journals and member of the Scientific Board of SINDEM, the Italian Neurological Society – Dementia
Latha Velayudhan, University of Leicester, Leicester General Hospital, Leicester, United Kingdom
Dr Latha Velayudhan is a clinical academic consultant old age psychiatrist working in the University of Leicester and the Leicestershire Partnership NHS Trust. She trained in Old Age Psychiatry at the South London & Maudsley NHS Foundation Trust, UK and completed MD(Res) at the Institute of Psychiatry, Kings College London. She currently leads the young onset dementia assessment service and her main research includes clinical and biological markers for Alzheimer’s disease, early onset dementia and risk of dementia with diabetes. She has published widely in the areas of dementia and is associate editor of Journal of Alzheimer’s disease.
Robert Vassar, Feinberg School of Medicine, Northwestern University Interdepartmental Neuroscience, Chicago, IL, USA
Robert Vassar, Ph.D., is Professor of Cell and Molecular Biology at the Feinberg School of Medicine, Northwestern University. He received his Ph.D. in Molecular Genetics and Cell Biology from the University of Chicago in 1992 with Dr. Elaine Fuchs and did his post-doctoral research with Dr. Richard Axel at Columbia University. Dr. Vassar joined Amgen, Inc., in 1996 where he co-discovered BACE1, a prime Alzheimer’s disease drug target. After leaving Amgen in 2001, Dr. Vassar joined Northwestern where he continues to investigate the role of BACE1 in health and Alzheimer’s disease.
Christopher Whiteley, National Taiwan University of Science and Technology, Taipei, Taiwan
Emeritus Professor Biochemistry; Rhodes University; Grahamstown; South Africa. Distinguished; Research Professor, National Taiwan University Science & Technology; Visiting International Professor in Enzymology; School Bioscience & BioEngineering; South China University Technology; Guangzhou, China; 2007-2012; Visiting Research Scientist, Dept Chemical Engineering, National Taiwan University, Taipei, Taiwan, 2004; Visiting Professor of Biochemistry; Institute Biomedical Technology; Veterans General Hospital; Yang Ming University; Taipei, Taiwan; Visiting Professor of Enzymology & Organic Synthesis; Oregon State University; Corvallis, Oregon, USA; Visiting Professor of Organic Synthesis; University British Columbia; Vancouver, Canada; Int’nl Brain Research Organisation; Int’nl Society for Neurochemists (ISN); South African Society for Biochemistry and Molecular Biology.
Justin Yerbury, University of Wollongong, Wollongong, Australia
Dr Justin Yerbury, NHMRC Career Development Fellow, leads a laboratory centred on understanding the role of protein aggregation in motor neurone disease and dementia. Dr Yerbury completed his PhD in 2008 at UOW, working with Prof Mark Wilson on extracellular chaperones after which he undertook post doc positions including a fellowship at the University of Cambridge to work with Prof Christopher Dobson. He has since moved back to Wollongong to set up his own group which takes a cell and molecular biology approach to examining protein homeostasis and protein aggregation in neurodegeneration.
Phone:?(+44) 020 3807 3712
Abstract and Poster Presentations
All abstracts accepted for oral presentation are also automatically accepted for poster presentation